Answers are grounded in this paper and cite their sources.
Phenotypic screening identified an arylsulfonamide compound with activity against Trypanosoma cruzi , the causative agent of Chagas’ disease. Comprehensive mode of action studies revealed that this compound primarily targets the T. cruzi proteasome, binding at the interface between β4 and β5 subunits that catalyze chymotrypsin-like activity.
No takes yet. Share an insight, caveat, or question.
Lima et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: